Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC49H59ClN8O8S2 |
InChIKeyCWTFXHWWWKKEQI-QQRWPDCKSA-N |
CAS Registry2683008-37-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 09 Dec 2021 | |
Neoplasms | Preclinical | United Kingdom | 09 Dec 2021 |